Somewhat Positive Press Coverage Somewhat Unlikely to Impact Lannett Co (LCI) Stock Price
Media coverage about Lannett Co (NYSE:LCI) has been trending somewhat positive on Wednesday, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Lannett Co earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.5006432105861 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news headlines that may have impacted Accern’s rankings:
- Analysts Anticipate Lannett Co Inc (LCI) Will Post Quarterly Sales of $153.21 Million (americanbankingnews.com)
- (LCI) is up at $17.70 Lannett Receives Approval For… – Modern Readers (modernreaders.com)
- Lannett Receives Approval For Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg And 40 mg – Markets Insider (markets.businessinsider.com)
- Technical Snapshots for These Generic Drugs Stocks — Catalyst Pharma, Flexion Therapeutics, Supernus Pharma, and … – Markets Insider (markets.businessinsider.com)
- Lannett Scores FDA OK for Nexium Generic-Biotech Movers – TheStreet.com (thestreet.com)
Several research firms have weighed in on LCI. BMO Capital Markets reissued a “market perform” rating and issued a $20.00 target price (down previously from $26.00) on shares of Lannett Co in a research note on Thursday, August 24th. BidaskClub lowered Lannett Co from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 8th. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Lannett Co in a research note on Wednesday, August 23rd. Zacks Investment Research raised Lannett Co from a “sell” rating to a “hold” rating in a research note on Tuesday, July 11th. Finally, Deutsche Bank AG cut their target price on Lannett Co from $23.00 to $19.00 and set a “hold” rating on the stock in a research note on Monday, August 14th. One analyst has rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $21.80.
Lannett Co (LCI) traded up 0.56% during midday trading on Wednesday, hitting $17.80. The stock had a trading volume of 41,589 shares. Lannett Co has a 52 week low of $14.90 and a 52 week high of $33.53. The stock’s market capitalization is $663.66 million. The company’s 50 day moving average price is $17.96 and its 200-day moving average price is $20.79.
Lannett Co (NYSE:LCI) last announced its quarterly earnings data on Wednesday, August 23rd. The company reported $0.40 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.40. The company had revenue of $139.10 million for the quarter, compared to the consensus estimate of $139.01 million. Lannett Co had a positive return on equity of 19.80% and a negative net margin of 0.09%. The firm’s revenue was down 17.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.73 EPS. Equities analysts anticipate that Lannett Co will post $2.57 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/06/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-lannett-co-lci-stock-price.html.
About Lannett Co
Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.
Receive News & Stock Ratings for Lannett Co Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett Co Inc and related stocks with our FREE daily email newsletter.